Two US-guided Techniques for Greater Occipital Nerve Blocks (GON)
Primary Headache
About this trial
This is an interventional treatment trial for Primary Headache focused on measuring Primary Headache, Greater Occipital Nerve, Ultrasound, Chronic Pain, Cervicogenic, Occipital Neuralgia, Migraine, Tension type headache, Cluster headache
Eligibility Criteria
Inclusion Criteria:
- Features suggestive of occipital neuralgia: pain that begins in the upper neck and back of the head with radiation forward toward the eye and has an aching or burning character.
- Diagnosis of refractory primary headache, any type
- Baseline NRS headache score of > 4 refractory to conventional oral analgesic therapy (anti-inflammatory drugs, migraine prophylaxis and treatment drugs, opioids).
Exclusion Criteria:
- Ongoing litigation issues related to the patient's pain
- Pregnancy
- Allergy to steroids or local anesthetics
- Multiple serious comorbidities
- Age < 18 or age ≥ 80 years
- GON injection within last 3 months at time of entry into the trial
Sites / Locations
- Mount Sinai Hospital
- Toronto Western Hospital, University Health Network
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
US-guided Distal GON Block (Group D)
US-guided Proximal GON Block (Group P)
Needle placement for 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg will be performed under US guidance at the level of the superior nuchal line lateral to the external occipital protuberance, close to the occipital artery.
Needle placement for 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg will be performed under US guidance at the level of the bifid C2 spinous process laterally, between the inferior obliquus capitis and semispinalis capitis muscles.